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Summary
  Glutamate is the basic excitatory neurotransmitter acting via N-methyl-D-aspartate receptors 
(NMDARs). It co-regulates many important physiological functions, including learning, memo-
ry, and behaviour. An excess of glutamate, as well as NMDAR over-activity, produce pathologi-
cal effects. Glutamate-related neurotoxicity is involved in the pathogenesis of many neurological 
conditions. This article briefly describes the role of the glutamate system in the pathophysiology 
of brain ischemia, selected neurodegenerative disorders, and schizophrenia. It also reviews the 
current and potential future status of agents targeting NMDARs in neuropsychopharmacology.
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Streszczenie
  Glutaminian jest podstawowym neuroprzekaźnikiem pobudzającym, który działa na receptory 
NMDA. Związek ten jest współodpowiedzialny za regulowanie wielu ważnych fizjologicznych 
funkcji, wliczając w to uczenie się, pamięć i zachowanie. Nadmiar glutaminianu i nadaktywność 
receptorów NMDARs wywołuje patologiczne zmiany. Zjawisko neurotoksyczności zależnej od 
glutaminianu bierze udział w patogenezie wielu zaburzeń neurologicznych. Artykuł pokrótce 
opisuje rolę glutaminianu w patofizjologii udaru niedokrwiennego mózgu, wybranych chorób 
neurodegeneracyjnych i schizofrenii oraz omawia obecne i potencjalne znaczenie leków działa-
jących na receptory glutaminergiczne w neuropsychofarmakologii.
 Słowa	kluczowe:	 glutaminian	•	receptory	NMDA	•	neurotoksyczność	glutaminianu	•	antagoniści	receptora	
NMDA
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1. Glutamate receptors
In mammalian central nervous system synapses, glutama-
te is the major neurotransmitter mediating excitatory neu-
rotransmission. It is released from presynaptic vesicles, 
diffuses across the synaptic cleft, and acts on both me-
tabotropic and ionotropic glutamate receptors located in 
the presynaptic terminals and postsynaptic membranes of 
the brain and spinal neurons. Three ionotropic glutamate 
receptor subtypes can be distinguished, and they are na-
med according to their agonists: NMDAR (N-methyl-D-
aspartate receptor), AMPAR (a-amino-3-hydroxy-5-me-
thylisoxazole-4-propionic acid receptor) and KAR (kainate 
receptor). NMDARs are composed of protein complexes 
which form an intrinsic ion channel, permeable to mono-
valent cations (including Na+ and K+), and bivalent ones 
(mostly Ca2+). We also know of a metabotropic glutamate 
receptor coupled to a G intrinsic membrane protein [12,13].
NMDARs contain four subunits which are a combination of: 
NR1, NR2, and NR3, (encoded by genes GRIN1, GRIN2A-D, 
GRIN3A-B, respectively). There is consensus that NMDARs 
are tetramers composed of two NR1 subunits and two NR2 
subunits, less commonly including NR3 subunits. NR1 sub-
units exhibit basic NMDAR features and disruption of NR1 
genes abolishes NMDAR responses. This demonstrates that 
NR1 subunits are rather essential. There are eight different 
NR1 elements, generated by alternative splicing of a single 
gene. Four (A-D) NR2 compounds can be distinguished, 
located in various brain regions and playing a modulatory 
role in regards to NMDARs. It has been shown that the com-
bination of NR1 with different NR2 subunits results in di-
verse electrophysiological and pharmacological responses. 
NR1 and NR2A are ubiquitous, NR2B occurs in the fore-
brain, NR2C in the cerebellum, with NR2D being the rarest. 
There is a binding place in the channel pore for Mg2+, and 
at resting membrane potential, Mg2+ is attached to this bin-
ding site, blocking ion flow through the channel [3,12,22].
Generally, NMDARs occur in many but not all cerebral 
cortex neurons and some cortical astrocytes. They are mo-
stly located on dendrites. Immunocytochemical studies 
have revealed that NMDARs are less frequently found in 
the 4th layer than in layers 2 to 3 and 5 to 6, where they are 
preferentially expressed by pyramidal neurons. This is in 
agreement with the notion that afferent glutaminergic in-
put reaches the cerebral cortex through the thalamocortical 
pathway, formed by axons of the 4th layer. NMDA recep-
tors are localised in the postsynaptic membrane, organised 
by a multi-protein structure called the postsynaptic densi-
ty (PSD). These receptors, however, are mobile and move 
between the synaptic and extra-synaptic pools. The PSD 
is defined as a type of postsynaptic membrane that conta-
ins high concentrations of glutamate receptors, ion chan-
nels, kinases, phosphatases and associated proteins [2,13].
Considering the NMDAR molecular structure, one may 
surmise that they have a common membrane topology 
with a large extracellular N-terminus, a membrane region 
composed of three transmembrane segments, and differ 
in the cytoplasmic C-terminus, depending on the vario-
us subunits, which interacts with numerous intracellular 
proteins [3,22].
Opening of the channel pore by NMDAR requires the si-
multaneous binding of the major agonist – glutamate (which 
play a neurotransmitter role) and the co-agonist – glyci-
ne (or D-serine, which act as modulators). The glutama-
te binding site is located on the NR2 subunit, whereas the 
glycine binding site is located on the NR1 subunit. After 
presynaptic glutamate release, and with sufficient glycine 
concentration in the synaptic cleft, NMDAR activation takes 
place. When the membrane is depolarised, the voltage-de-
pendent Mg2+ block is removed from the channel interior, 
allowing for ion to enter. By contrast, AMPARs, composed 
of various combinations of four subunits ( GluR1-GluR4) 
are permeable to Ca2+ only in the absence of the GluR2 
element [3,12,13,22].
The general scheme of NMDA receptor structure together 
with the potential sites for pharmacological action descri-
bed below presents figure 1.
NMDARs can be divided into two classes according to the-
ir conductance properties: high conductance channels (bu-
ilt from NR2A or NR2B) and low conductance ones (for-
med by NR2C and NR2D) with reduced sensitivity to Mg2+ 
block. An influx of extracellular calcium initiates complex 
signalling pathways compromised of the mitogen-activa-
ted protein kinase (MAPK) superfamily that transduces 
excitatory signals across the neuron. Taking into conside-
ration in vitro substances, MAPKs have been also called 
microtubule associated protein-2 kinase (MAP-2 kinase), 
myelin basic protein kinase (MBP kinase), ribosomal S6 
protein kinase (RSK-kinase) and epidermal growth factor 
(EGF) receptor threonine kinase (ERT kinase). MAPK ac-
tivation was observed in response to NMDARs stimulation, 
starting with tyrosine phosphorylation of MAPKs. An ad-
ditional class of kinases, named MAP kinase kinases and 
MAPK kinase kinases (MAPKK kinases), are then excited, 
through an intermediate step involving MAPK stimulation. 
Usually, three MAPKs are distinguished: extracellular si-
gnal-regulated kinase-1 (ERK1 and 2), the Jun N-terminal 
kinases (JNKs) activating Jun transcription factor, and the 
p38 MAPKs. The two last ones are called stress-activated 
kinases (SAPKs), because they are stimulated by stressful 
conditions. Consequently, the transcription factor cAMP-
-Ca2+ response element-binding protein (CREB) causes 
the expression of genes that encode brain-derived neuro-
trophic factor (BDNF) and other factors promoting neuro-
nal survival and activity [5,9,24,27]. Detailed information 
 Abbreviations:	 AD – Alzheimer’s disease; ALS – Amyotrophic lateral sclerosis; AMPAR – a-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid receptor; CJD – Creutzfeld-Jacob disease; EAATs – Excitatory 
aminoacids transporters; GABA – g-aminobutyric acid; glyT1 – glycine transporter 1; HD – 
Huntington disease; KAR – Kainate receptor; LTD – Long term depression; LTP – Long term 
potentiation; MAPK – Mitogen activated protein kinase; NMDAR – N-methyl-D-aspartate receptor; 
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concerning NMDAR and MAPK signalling is given in an 
excellent review prepared by Haddad [9].
AMPARs, similar to NMDARs, couple to the MAPK pa-
thways through similar sets of signalling systems and with 
Ca2+ entrance resulting in the synthesis of CREB and other 
transcription factors. However, AMPARs also can activa-
te MAPK through Ca-independent mechanisms through 
the SRC-family tyrosine kinase. In summary, at the mo-
lecular level NMDARs interact with MAPKs, creating a 
neurochemical axis that regulates neuronal functions [6].
As a side note, it should be mentioned that the glutama-
te system changes together with development and growth. 
GABA (g-aminobutyric acid), the main inhibitory neuro-
transmitter in the adult central nervous system, acts as an 
excitatory neurotransmitter in the early postnatal state, in-
fluencing its GABA-A receptors. It has been revealed that 
GABA-A receptor activation depolarizes neuroblasts and 
immature neurons in all brain regions. It is unknown why 
GABA operates as an excitatory agent in neonatal neuro-
nes while being an inhibitory one in later stages. Factors 
responsible for the shift from this excitatory to inhibito-
ry action have not been determined so far. Moreover, glu-
taminergic transmission is initially purely mediated by 
NMDARs, without any contribution of AMPA receptors. 
Thus, these three receptors exhibit a sequential participa-
tion in neuronal excitation [1].
2. Glutamate and synaptic plasticity
The glutamate system is thought to be involved in learning 
and memory processes. It is associated with the phenomenon 
of synaptic plasticity – the variable efficacy of neurotransmis-
sion which enables the brain to store memories and experien-
ces. This phenomenon requires gene transcription and pro-
tein synthesis to stabilize synaptic changes over time. Both 
NMDA and AMPA receptors are suspected in regulating sy-
naptic plasticity, however the consensus exists that AMPARs 
are responsible for short-term changes in synaptic strength, 
while NMDARs affect genes that are necessary for long-term 
maintenance of these changes. In short, AMPAR depolarisa-
tion of the postsynaptic membrane facilitates NMDAR acti-
vation, which in turn modulates surface AMPAR presence. 
Thus, postsynaptic changes develop changes in the synap-
tic strength which is characterised by long-term potentiation 
(LTP) or long-term depression (LTD) [16,25].
LTP is defined as a strengthening of synaptic transmission 
that is long lasting (at least more than an hour), commonly 
induced by brief, high-frequency stimulation. LTD is regar-
ded as being long-lasting suppression of synaptic strength 
that is elicited by low frequency stimulation, typically re-
sulting from NMDAR activation. LTP is believed to be a 
key molecular element involved in learning and memo-
ry, while LTD is said to be the means by which we obta-
in information storage and consolidation in the brain [16].
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Both LTP and LTD are forms of associative plasticity based 
on positive feedback, counteracting both the maximum and 
minimum synaptic strength changes in an effort to norma-
lise neuronal excitability. Decreased neuronal activity le-
ads to a homeostatic increase in the strength of excitatory 
synapses, while increased neuronal activity has the oppo-
site effect. This preserves the balance between both exci-
tatory and inhibitory synapses, termed synaptic scaling. 
Under basal conditions, the ratio of the relative activities 
of NMDARs and AMPARs is about 1:1. During “pre-LTP”, 
the ratio between AMPARs and NMDARs is disturbed be-
cause of AMPAR postsynaptic expression. This decreases 
the NMDAR: AMPAR ratio (1:3) and triggers postsynap-
tic removal, a decrease in the number of AMPA receptors, 
and proportional NMDAR potentiation. The result of these 
processes is a LTP state. While the ratio between NMDARs 
and AMPARs is restored (1:1), the synapses become twi-
ce as strong, with twice as many AMPARs and NMDARs 
as in the “pre-LTP”state [25].
3. Glutamate excitotoxicity in pathophysioloGy of selected 
neuroloGical disorders. the potential role of nmdar 
antaGonists in pharmacotherapy
As summarised above, glutamate and glutamate receptors 
are engaged in cognition and behaviour control. However, 
an excessive amount of glutamate and over-activation of 
glutamate receptors leads to neuronal cell injury. Thus, the 
same processes which are essential and critical for normal 
neuronal functioning, in excess lead to excitotoxic cell de-
ath. This phenomenon is termed glutamate-related excito-
toxicity and was first used by John Olney in 1970 [16,21].
The mechanisms of excitotoxicity arise from many factors. 
In pathological conditions, an excessive Ca2+ influx into 
the neuron promotes various processes resulting in dendri-
tic and/or synaptic damage and cell necrosis or apoptosis. 
This is the consequence of Ca2+ mitochondrial overload, 
causing oxygen free radical formation, caspase activation, 
and intracellular protein degradation. This calcium overlo-
ad also causes Ca-dependent activation of neuronal NOS 
which in turn causes overproduction of toxic peroxynitri-
te ion (ONOO–). An important element of excitotoxicity 
is the stimulation of mitogen-activated protein kinase p38 
(MAPK p38) which activates transcription factors affec-
ting neuronal apoptosis [13,17].
The phenomenon of excitotoxicity is a target of both neu-
roprotective efforts and modern pharmacotherapy since it 
is implicated in the pathophysiology of many acute and 
chronic neurological diseases mentioned below.
3.1. Traumatic brain injury
Many factors may lead to an excessive glutamate presen-
ce. One of them is mechanical insult – head or spinal cord 
injuries lead to a sudden, large glutamate release from in-
jured neurons. This “fast” excitotoxicity in traumatic bra-
in injury (TBI) has been confirmed in both animal mo-
dels and human studies. It points to the neuro-protective 
potential of NMDAR antagonists in TBI treatment. Some 
experimental evidence supports this hypothesis, although 
several clinical programmes were terminated premature-
ly because of failure to find any benefits in using the same 
agents as in clinical trials dealing with stroke (see below). 
Selfotel and dexanabinol, some of the agents studied in 
TBI, were found to have no impact on mortality or clinical 
outcomes; however the number of participants was inade-
quate to determine unambiguous benefits and risks. Data 
from other studied agents (aptiganel and eliprodil) rema-
in inadequately reported [13,19].
3.2. Ischemic stroke
The next important set of entities manifesting in a sudden 
and high glutamate delivery are neuronal ischemic events. 
During an ischemic stroke, energy deprivation of membra-
ne protein pumps causes many neurons to lose their abi-
lity to maintain ionic homeostasis. This causes their de-
polarization, lysis, and/or autodestruction, similar to that 
observed in traumatic injury. Energy failure causes abnor-
mal glutamate accumulation and prolonged synapse acti-
vation, mostly because of impaired glutamate re-uptake 
into astrocytes [11,17,19].
Among all studied entities, the preclinical rationale for acu-
te brain ischemia treatment with non-selective NMDAR 
antagonists was possibly the strongest. Nevertheless, cli-
nical studies with these agents have failed so far. The re-
asons for this failure are multifactorial. First, there have 
been many difficulties regarding the methodology of con-
ducted clinical trials: patient selection, problems with blin-
ding, random allocation of treatment dose, and interactions 
of drugs with anaesthetic agents. Moreover, experimental 
studies suggest that NMDAR antagonists are most effecti-
ve when given in the pre-ischemia phase or up to two hours 
after induction of ischemia – patients were often diagno-
sed and treated at a later time, beyond the short therapeu-
tic time window. Moreover, the levels of the studied agents 
cannot be easily measured in the brain, and plasma con-
centrations determined in previous studies were consisten-
tly below values needed for maximal protection as repor-
ted in animal models. On the other hand, higher doses of 
NMDAR antagonists were reported to induce serious side 
effects: psychomimetic effects (hallucinations, agitations, 
peripheral sensory disturbances), a centrally mediated in-
crease in blood pressure, nausea, vomiting and catatonia. 
These disadvantages could have been circumscribed if 
NR2B selective NMDAR antagonists – ifenprodil or tra-
xoprodil were administrated since they produce minimal 
side effects. However, the enthusiasm for these appro-
aches has diminished because of their variable neuropro-
tective efficacy. This may be associated with reduced af-
finity and unbinding from inactivated NMDARs, leading 
to transient activation of unaffected receptors. Thus, fur-
ther studies are required, particularly in order to determi-
ne the receptor mechanism. There are also efforts to intro-
duce another NMDAR antagonist – gavestinel – in stroke 
pharmacotherapy [13,19].
At present, the basic treatment for stroke is still thrombo-
lytic therapy.
3.3. Neurodegenerative disorders
A high glutamate level is also involved in the pathophy-
siology of many slowly progressive neuronal disorders. 
The concept of “slow excitotoxicity” was developed as a 
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pathogenetic factor explaining the gradual neuronal loss 
in neurodegenerative diseases such as Alzheimer’s dise-
ase (AD), Huntington’s disease (HD), Parkinson’s disease 
(PD), multiple sclerosis, HIV-associated dementia, and 
amyotrophic lateral sclerosis (ALS). In these diseases, it 
is suspected that long-term exposure to moderate levels of 
glutamate causes NMDARs hyperactivity, resulting in the 
apoptotic-like cell death of neurons [17,19].
For many years, NMDAR antagonists have been known 
to be effective in animal models of Parkinson’s disease 
(PD) which could be explained by the pathophysiological 
premises of PD. The depletion of nigrostratial dopamine 
produces over-activation of glutaminergic pathways to the 
stratium, which contributes to dyskinesia. Amantadine, a 
low-affinity NMDAR blocker, is used as an adjuvant the-
rapy in PD (especially because of its additional ability to 
enhance dopamine release and impair dopamine re-upta-
ke). It improves levodopa-induced dyskinesias (see fur-
ther). Some preclinical studies have shown that non-se-
lective NMDAR antagonists act in a synergistic way with 
levodopa and dopamine agonists. Remacemide is a sodium 
channel blocker and its principal metabolite – remacemi-
de desglycine – is a low affinity uncompetitive NMDAR 
antagonist. The reports of some clinical trials suggest im-
proved overall motor function, however these results were 
not statistically significant [10,13,19]. This drug was also 
tested for treatment of refractory focal seizures, showing 
its efficacy after 14 to 15 weeks of administration in three 
clinical trials including over 500 patients. Dizziness was 
a notable side effect. These agents also have pharmacoki-
netic interactions with several conventional anti-epileptic 
drugs. The exact mechanism of remacemide action in epi-
lepsy is unknown, but a general agreement exists amongst 
researchers that NMDAR participation in the pathogene-
sis of epilepsy is without any doubts. A strong argument 
supporting this hypothesis is the efficacy of felbamate the-
rapy [19,26].
A low-affinity uncompetitive antagonist – memantine – has 
also been studied as a treatment for dementias including 
Alzheimer’s disease (AD, see the last chapter). Considering 
the role of NMDARs in cognition, it seems irrational that 
NMDAR antagonists may improve AD symptomatology 
[13,19]. On the other hand, there are links between exci-
totoxicity and AD development. Misfolded mutant prote-
ins are thought to be implicated in the pathogenesis of this 
disease, especially soluble oligomers of b-amyloid (Ab) 
peptide and hyperphosphorylated tau proteins. Oxidative 
stress and intracellular Ca2+ influx both enhance synthesis 
of these proteins. Moreover, Ab increases the NMDAR re-
sponse and inhibits glutamate re-uptake. Thus, NMDAR 
disturbances are secondarily co-responsible for AD deve-
lopment, also diminishing learning and memory functio-
ning [17]. Preclinical studies have reported that a small an-
tagonism of NMDARs improves learning of certain tasks, 
although the precise mechanism underlying this observa-
tion remains unknown.
There are also reports indicating that NMDAR distur-
bances participate in neurodegeneration associated with 
Creutzfeld-Jacob disease (CJD). The endogenous cellular 
prion protein PrPC protects from excitotoxicity by down-re-
gulating the NMDAR subpopulation. CJD is characterised 
by a progressive misfolding of the PrPC form into a patho-
logical PrPSc form, that may contribute to a neuroprotec-
tive function loss, leading subsequently to excitotoxicity 
and neurodegeneration [12].
3.4. Schizophrenia
Contrary to previous findings, there is evidence indicating 
that potentiating NMDARs seems be beneficial for schizo-
phrenia treatment. Schizophrenia is a chronic psychiatric 
condition characterized by positive, negative and cogniti-
ve symptoms. Positive symptoms include hallucinations, 
delusions, disorganised speech and behaviour. Negative 
symptoms include flattened or restricted affect and lack of 
motivation. Cognitive symptoms include progressive me-
mory and learning disturbances and symptoms associated 
with cortical processing [14].
The pathophysiology of schizophrenia is associated with 
several neurotransmitter systems. A common theory exi-
sts implicating altered dopaminergic transmission in schi-
zophrenia development. However, a different hypothesis 
implicates glutamate in the pathogenesis of schizophre-
nia. This second hypothesis arises from studies revealing 
that administration of non-competitive NMDAR antagoni-
sts (such as phencyclidine or ketamine) disrupts cognitive 
and behaviour functions, producing a schizophrenia-like 
syndrome, recapitulating both positive and negative symp-
toms. When administrated to schizophrenic patients, these 
antagonists can worsen symptoms. These findings indica-
te that schizophrenia is also characterized by diminished 
glutamate system and NMDAR activity. Thus, achieving 
an increase in the activity of the glutamate system through 
the administration of dopaminolytic agents seem to be a 
logical therapeutic option [7,14,15,20].
3.5. NMDARs in pain
There are findings supporting a hypothesis that NMDARs 
are co-responsible for nociception. Animal studies reve-
aled that NMDARs are located in unmyelinated and my-
elinated axons of peripheral tissues. It has been demon-
strated that peripheral nociceptive fibres express NR2B 
and NR2D subunits of NMDARs, while NR2A subunits 
appear to be absent from afferent terminals. Consistent 
with this, local glutamate injection results in nocicepti-
ve behaviour. Use of NR2B-selective antagonists poten-
tiates NMDAR inhibition and should alleviate pain esthe-
sia. NMDAR numbers increase in inflammatory changes, 
contributing to allodynia and hyperalgesia that both have 
a peripheral and a central component. Allodynia results 
from low-intensity stimuli acting via low-threshold affe-
rents, generating pain. The phenomenon of hyperalgesia 
develops from noxious input that generates a pain respon-
se but with augmented amplitude and duration. The central 
sensitisation of the spinal cord is mediated by presynap-
tic NMDAR activation. Many primary afferents termina-
ting in the dorsal horn express NMDARs and activation of 
presynaptic NMDARs results in the release of substance 
P (SP), calcitonin gene related peptide (CGRP), and glu-
tamate from primary afferents. This facilitates and pro-
longs nociceptive transmission to the central nervous sys-
tem, resulting in an elevation of dorsal horn excitability. 
The NMDAR-induced increased nociception seems also 
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to be related to a disinhibition phenomenon – a blockade 
of inhibitory mechanisms which should suppress hypere-
sthesia. Disinhibition may be a consequence of a reduc-
tion in inhibitory neurotransmitters such as GABA (g-ami-
nobutyric acid), disturbed or diminished GABA receptors 
or loss of inhibitory neurons. In physiological conditions, 
the excessive participation of NMDARs in synaptic trans-
mission is prevented by GABA-A receptor mediated hy-
perpolarizing currents. Lack of this inhibition after GABA 
system deprivation and low-intensity stimulation begins to 
induce central sensitization which never takes place under 
physiological states [4,19,23].
At present, glutamate antagonists are proposed to be ef-
fective in postoperative pain. Postoperative hyperalgesia is 
a complex modulated by peripheral, spinal and supra-spi-
nal level perception, caused by several physiopathologic 
mechanisms. Postoperative pain involves many neurotran-
smitter systems that either facilitate or inhibit nociception 
of somatic, neuropathic, inflammatory or visceral origins. 
Ketamine is a well-known NMDAR antagonist agent with 
a confirmed efficacy in reducing surgery-induced hyperal-
gesia. This drug was developed as an anaesthetic agent and 
has been demonstrated to cause “dissociative anaesthetics.” 
Many small trials confirm the adjuvant role of ketamine in 
subanaesthetic doses during analgesia. On the other hand, 
ketamine must be administrated via a systemic route to pro-
duce its analgesic effect, excluding the suspected direct 
neuronal NMDAR blocking. The mechanism of action of 
systemic ketamine may be related to different elements – 
this drug produces multiple pharmacologic effects and in-
teracts with many systems that mediate analgesic effects 
unrelated to NMDAR antagonism. Ketamine is an agonist 
of opioid receptors, exhibits inhibition of neuronal nico-
tinic receptors and activates the mono-aminergic descen-
ding inhibitory system that modulates nociception in the 
dorsal horn. Ketamine also suppresses the production of 
pro-inflammatory cytokines (TNF-a, Il-6) and exerts a di-
rect anti-inflammatory effect on macrophages. Thus, these 
other ketamine actions, rather than pure NMDAR antago-
nism, may account for the efficacy of this drug in posto-
perative pain management [4,23,28].
Apart from ketamine, several other drugs posses antago-
nistic NMDAR properties. Dextrometorphan, a D-isomer 
of the codeine analogue levorphanol, was shown to inhi-
bit central sensitization in experimental studies. However, 
clinical use has been disappointing. Patients receiving de-
xtrometorphan parenterally reported less pain in the ear-
ly postoperative period, although the results were inconc-
lusive. As a side note, dextrometorphan is being tested in 
clinical trials involving children suffering from Rett’s syn-
drome – a neurodevelopmental disease affecting mostly 
females, characterized by the development of autistic fe-
atures, stereotypic hand movements and epileptic attacks 
[4,23,28]. Other opioid analgesics, such as methadone or 
buprenorphine, also have anti-NMDAR properties at lo-
wer doses than those needed to induce complete analgesia. 
Anticonvulsant drugs such as gabapentin also display an-
ti-hyperalgesic properties and have the ability to modula-
te glutaminergic neurotransmission. Nefopam, a centrally 
acting analgesic, also diminishes glutamate receptor acti-
vity and prevents postoperative opioid overconsumption. 
Selected non-steroidal anti-inflammatory drugs such as 
ketorolac, demonstrate a central analgesic effect involving 
modulation of NMDAR activity [4,23,28].
In summary the inhibition of the glutaminergic system is 
suspected to be involved in the pain-relief mechanism of 
many drugs. Ketamine may also have a role in pre-empti-
ve analgesia for surgical procedures, however, this comes 
at the expense of a small increase in the risk of psychomi-
metic effects. At present, there is no evidence supporting 
an unambiguous rationale for other NMDAR antagoni-
sts in both acute and chronic pain. This area needs further 
study in the future.
4. nmdar-tarGetinG aGents – current therapies and 
future perspectives
Early preclinical and clinical trials of glutamate targeting 
drugs concentrated on NMDARs and three main types of 
antagonists have been studied: competitive NMDAR an-
tagonists (glutamate – e.g. selfotel or glycine binding site 
– e.g. gavestinel), non-competitive allosteric drugs, and/
or NMDAR channel blockers. As was mentioned before, 
these agents were not effective for the following indica-
tions: ischemic stroke, and TBI, because of the restrictions 
discussed above. Further development of these NMDAR 
antagonists is unlikely and the initial enthusiasm for this 
kind of therapy has been abolished [12,13,19].
Lack of success caused a diminished interest in the glu-
tamate system as a potential target of modern pharmaco-
therapy. It was surprising to find that well-tolerated drugs 
with multiple mechanism of action, demonstrating benefits 
for some neurological conditions, also exhibit anti-NMDA 
properties. These were mentioned above: felbamate, rilu-
zole, amantadine and memantine.
Felbamate was initially screened for anticonvulsant acti-
vity in experimental models and showed a broad antico-
nvulsant profile similar to valproic acid but with less neu-
rotoxicity. The complex pharmacodynamic mechanism 
of felbamate involves inhibition of voltage-dependent 
Na+ and Ca2+ channels as well as NMDAR antagonism. 
These drugs seem to be a non-competitive allosteric inhi-
bitors with some selectivity for NR2B-containing recep-
tors. During clinical trials, felbamate produced no adverse 
side effects specific to other anti-epileptic drugs or anta-
gonists tested in TBI and ischemic stroke. The most com-
mon reported side effects of felbamate were nausea, ano-
rexia and insomnia. However, pharmacovigilance studies 
published after the introduction of this agent to common 
clinical practice revealed two rare but of special importan-
ce reactions related to felbamate: aplastic anaemia (with 
incidence of about 1:8000) and hepatotoxicity (1:26000). 
These unexpected adverse events have limited felbamate 
clinical use – nowadays this drug is recommended only in 
intractable partial seizures and in Lennox-Gastaut syndro-
me that is refractory to primary therapy [12].
Riluzol was also developed as an anticonvulsant agent, but 
findings demonstrating its modulatory effects in NMDAR-
mediated neuronal death caused that further development 
of riluzol was geared towards its neuroprotective func-
tions. It was discovered that riluzol is a Na+ channel bloc-
ker in NMDAR containing neurons and that it prevents the 
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entrance of neuronal Ca2+, stabilising NMDARs and pro-
tecting them from depolarization. This drug also enhanced 
glutamate clearance from the synaptic cleft by increasing 
glutamate re-uptake. The most promising results of rilu-
zol were in clinical trials obtained for amyotrophic lateral 
sclerosis (ALS). The drug showed a statistically significant 
survival advantage and a 9% absolute risk reduction com-
pared to placebo. Patients receiving riluzol reported small 
beneficial effects on limb function. The drug was well tole-
rated with asthenia, nausea and elevation of liver enzymes 
being the most frequent side-effects. Although the efficacy 
of riluzol in treating ALS was not acceptable, the drug was 
still approved in many countries for ALS treatment [12].
Amantadine was introduced into clinical practice for the 
prophylaxis of respiratory infections due to influenza. It was 
discovered that this drug had anti-Parkinsonian properties 
through direct dopaminergic activity. Further studies re-
vealed that amantadine is also an NMDAR antagonist ac-
ting as an open-channel blocker. Further clinical trials are 
still needed to establish this drug’s value in PD [10,12,19].
Memantine was synthesised as a potential hypoglycaemic 
agent, however it was ineffective in lowering glucose blo-
od level. On the other hand it was observed that cognitive 
functions of diabetic patients treated with memantine were 
improved, thus this drug was used in the treatment of de-
mentia. Memantine, similar to amantadine, was discovered 
to be an open-channel NMDARs blocker but it was shown 
to have a relatively low affinity for NMDARs, allowing 
fast binding but also rapid dissociation from the receptors. 
Moreover, the action of memantine is voltage-dependent 
and therefore, this agent did not block NMDAR channels 
upon strong postsynaptic depolarization (which is speci-
fic during physiological conditions). The NMDARs were 
blocked during moderate, long-lasting depolarization, ob-
served in pathological, excitotoxic conditions. Memantine 
was also shown to inhibit nicotinic cholinergic receptors 
that, when activated, also contributes to amyloid-b – in-
duced tau protein phosphorylation and AD development. 
This drug was well-tolerated with nausea, diarrhoea, he-
adache, insomnia, and dizziness being the most serious 
adverse effects. It was approved for moderate and severe 
AD treatment in most of the European countries, the USA 
and Canada. Clinical trials were carried out on memantine 
in the treatment of frontotemporal lobar degeneration, PD 
dementia, cognitive symptoms related to Huntington’s di-
sease, and cognitive dysfunction in the course of TBI; this 
drug may also be neuroprotective in these entities [12,19].
It should be mentioned that novel agents focused on AD tre-
atment are being developed. There are two other NMDAR 
targeting agents currently being studied: neramexane and 
dimebon. Neramexane, similarly to memantine, is an open-
-channel NMDAR blocker and displays a similar pharma-
cokinetic and comparable clinical tolerability. Dimebon, 
which was initially classified as an antihistaminic drug, is 
being studied as a potential agent for AD and HD becau-
se it also blocks NMDARs [12].
Prospective NMDAR antagonists and other agents affecting 
the glutamate system are based on two major strategies, 
which do not target the extracellular part of NMDARs, as 
other medications have so far.
The first novel strategy is based on the transporter systems 
regulating the glutamate amount in the synaptic cleft and 
the second one targets intracellular proteins which are in-
volved in NMDAR signalling pathways.
Glutamate released into the synaptic cleft is then remo-
ved using a family of excitatory amino acids transporters 
(EAATs). The idea of developing glutamate re-uptake ac-
tivators arose thanks in part to the theory behind selecti-
ve serotonin re-uptake inhibitors. There are five types of 
EAATs (EAAT1 – EAAT5) with EAAT2 responsible for 
most of the glutamate turnover in the brain. Agents incre-
asing EAAT2 activity or its membrane expression on both 
neurons and glia might provide new a therapeutic appro-
ach in reducing glutamate-mediated excitotoxicity becau-
se of glutamate clearance enhancement. It was found that 
ceftriaxone, a beta-lactam antibiotic, increases EAAT2 ac-
tivity in mouse models of ALS. It is currently going thro-
ugh clinical trials in regards to this. There are also reports 
that riluzol, with its complex mechanism of action, also 
increases the activity of EAAT2 [12].
Among signalling proteins, there are many potential en-
zymes (such as protein kinases and phosphatases) which 
may act as modulatory sites by interfering in signalling do-
wnstream to the nucleus. The idea behind such agents al-
ready exists in modern oncology. Several molecules dri-
ving neoplastic transformation have been identified. This 
has allowed us to develop designed cancer therapeutics 
which can inhibit intracellular neoplastic signal transduc-
tion. An example of this are monoclonal antibodies (ima-
tinib or trastuzumab). One molecular target that regulates 
NMDAR activity is protein kinase C. In animal studies, it 
was demonstrated that inhibition of this enzyme impairs 
spatial memory. Consequently, artificial elevation of pro-
tein kinase C activity might be especially effective in neu-
rological disturbances with memory impairment (AD and 
other dementias). Studies concerning protein kinase C ac-
tivators are ongoing, with the most advanced studies invo-
lving bryostatin-1 and nefiracetam [12].
As mentioned above, there are attempts to increase glu-
tamate system function and NMDAR activity in schizo-
phrenia. Already some opportunities exist when it comes 
to enhancing NMDAR function. Some drugs have alre-
ady been studied in pre-clinical and clinical trials. Direct 
glutamate agonists may be used, although their applica-
tion is limited because of possible overdosing and excito-
toxicity. Other therapeutic opportunities involve the use of 
NMDAR modulatory site agonists, especially agonists ac-
ting on the glycine/D-serine site. When administrated to-
gether with classic neuroleptic agents, they significantly 
improved symptoms. The antibiotic D-cycloserine is a par-
tial glycine site agonist that improves glutaminergic activi-
ty in schizophrenia, however, further studies are required 
to establish its usefulness in the treatment of this disease. 
Pilot studies suggesting that the core symptoms of social 
impairment in patients with autism may be improved when 
the patients are treated with D-cycloserine are under way.
An interesting approach in the development of antipsy-
chotic agents involves the glutamate system. This appro-
ach increases extracellular glycine levels through re-upta-
ke inhibition (by blocking the glyT1-transporter), similar 
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Drug Pharmacological profile Studied therapeutic area Remarks
NMDAR antagonists
Selfotel Competitive NMDA antagonist at glutamate binding site StrokeTBI Most clinical trials were
terminated prematurely with
trends towards worse
functional outcome or
higher mortality –
however, they were
methodologically controversial 
Gavestinel Competitive NMDA antagonist at glycine binding site Stroke
Eliprodil
Traxoprodil Competitive NMDA antagonist at NR2B binding subunit 
Stroke
TBI
Aptiganel High affinity uncompetitive ion channel blocker StrokeTBI
Amantadine Low affinity NMDA antagonist PD
Memantine Low affinity NMDA antagonist ADPD
Complex action; also inhibits
nicotinic Ach receptors (nAchRs)
Felbamate Uncompetitive NMDA antagonist Intractable partial seizuresLennox-Gastaut Syndrome
Complex action, also inhibits
voltage gated Na+ and Ca2+ 
channels 
Riluzol Uncompetitive NMDA antagonist ALS
Complex action, also inhibits
voltage gated Na+ and Ca2+ 
channels
Remacemide Uncompetitive NMDA antagonist Epilepsy, PD Complex action, also inhibitsNa+ channels
Dexanabinol Uncompetitive NMDA antagonist TBI
Synthetic cannabinoid with
antioxidant and anti-
inflammatory
properties
Ketamine Low affinity NMDA antagonist Analgesia
Complex action, also affects
opioid receptors, activates
descending monoamine
antinociceptive system and
displays anti-inflammatory
properties 
Dextrometorphan Low affinity NMDA antagonist AnalgesiaRett’s Syndrome
Complex action, also affects
opioid receptors
Neramexane NMDA open channel blocker AD
Dimebon NMDA blocker at a site distinct from memantine AD Complex action, also inhibitsH1 receptors
EAATs upregulators – glutamate reuptake enhancers
Ceftriaxon Increases EAAT2 activity and glutamate clearance ALS
Riluzol Increases EAAT2 activity and glutamate clearance ALS
Signalling proteins modulators
Bryostatin-1 Protein kinase C activators AD
Nefiracetam Protein kinase C activators AD
Glycine agonists
D-cycloserine NMDA agonist at glycine site Schizophrenia
glyT1 upregulators – glycine reuptake inhibitors
Sarcosine Decreases glyT1 activity and glycine clearance Schizophrenia
Table 1. NMDAR-targeting agents [12,19]
NMDA – N-methyl-D-aspartate, TBI – Traumatic Brain Injury, PD – Parkinson Disease, AD – Alzheimer Disease, ALS – amyotrophic lateral sclerosis, 
EAATs – Excitatory Amino Acids Transporters, EAAT1 – Excitatory Amino Acid Transporter 1, glyT1- Glycine Transporter 1
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